Comparative Pharmacology
Head-to-head clinical analysis: ALKERAN versus CARMUSTINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALKERAN versus CARMUSTINE.
ALKERAN vs CARMUSTINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alkylating agent that crosslinks DNA, inhibiting DNA synthesis and transcription, leading to apoptosis.
Carmustine is a nitrosourea alkylating agent that forms interstrand crosslinks in DNA, thereby inhibiting DNA replication and transcription. It is cell cycle phase-nonspecific and also has some alkylating activity against RNA and proteins.
Melphalan (Alkeran): 0.25 mg/kg/day orally for 4 consecutive days, repeated every 6 weeks; or 16 mg/m^2 IV over 15-20 minutes every 2 weeks for 4 doses, then every 4 weeks.
150-200 mg/m2 intravenously every 6 weeks as a single dose or divided into daily doses of 75-100 mg/m2 on 2 consecutive days every 6 weeks.
None Documented
None Documented
Clinical Note
moderateCarmustine + Digoxin
"Carmustine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCarmustine + Digitoxin
"Carmustine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCarmustine + Deslanoside
"Carmustine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCarmustine + Acetyldigitoxin
"Carmustine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 1.5–2.5 hours (may extend to 4–5 hours in renal impairment); clinically relevant for dosing interval and myelotoxicity monitoring.
Terminal half-life 15-30 minutes (biphasic: initial 1-4 min, terminal due to slow release from tissues); prolonged with hepatic impairment
Renal: 20–50% as unchanged drug and metabolites; fecal: minor (<10%); biliary: negligible.
Renal (60-70% as metabolites); <1% unchanged; biliary/fecal minimal (~6%)
Category C
Category C
Alkylating Agent Antineoplastic
Alkylating Agent Antineoplastic